Overview

Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy

Status:
Completed

Trial end date:
2007-12-01

Target enrollment:

Participant gender:

Summary

Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan, with weekly vincristine, temozolomide and vantin; to evaluate the feasibility of repetitive cycles of this chemotherapy and to estimate the response rate to this combination in children and adolescents with recurrent solid tumors and lymphomas.

Phase:

Phase 1

Details

Lead Sponsor:

University of Oklahoma

Treatments:

Anti-Bacterial Agents
Irinotecan
Temozolomide
Vincristine